Company: VRCA
Filing Date: 2025-01-30
Form Type: 8-K
Source: 0001193125-25-017264
Chunk: 1

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-01-30
Form: 8-K
Item: Item 3.01
Chunk 1
---
 of common stock will be subject to delisting. At such time, the Company may appeal the delisting determination to a Hearings Panel.

The Company intends to actively monitor its minimum bid price of listed securities and, as appropriate, will consider available options to resolve the deficiencies and regain compliance with the Nasdaq Listing Rules, including applying to transfer to the Nasdaq Capital Market or effecting a reverse stock split.

There can be no assurance that the Company will be successful in maintaining the listing of its common stock on the Nasdaq Global Market, or, if transferred, on the Nasdaq Capital Market.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                              Verrica Pharmaceuticals Inc.     
  Date: January 30, 2025      /s/ John J. Kirby                
                              John J. Kirby                    
                              Interim Chief Financial Officer